An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
Special items: Ovarian Cancer and Us blog best viewed in Firefox
▼
Sunday, July 29, 2012
A phase I trial of dasatinib, a Src-family kinase Inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.